Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss - Benzinga
FDA approves Eli Lilly's Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor for moderate-to-severe atopic dermatitis in adults and children 12+ years old who weigh at least 88 lbs and have uncontrolled eczema despite topical treatments. Ebglyss, a 250 mg/2 mL injection, can be used with or without topical corticosteroids, with an initial dose of 500 mg at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16, then monthly maintenance. Studies showed 38% achieved clear or almost clear skin at 16 weeks (vs. 12% placebo), with 77% maintaining results at one year.
Reference News
FDA approves Eli Lilly's Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor for moderate-to-severe atopic dermatitis in adults and children 12+ years old who weigh at least 88 lbs and have uncontrolled eczema despite topical treatments. Ebglyss, a 250 mg/2 mL injection, can be used with or without topical corticosteroids, with an initial dose of 500 mg at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16, then monthly maintenance. Studies showed 38% achieved clear or almost clear skin at 16 weeks (vs. 12% placebo), with 77% maintaining results at one year.